Predicting Response to Neoadjuvant Chemotherapy Using Optical Tomographic Imaging in Women with Breast Cancer
Using New Imaging Technique in Women with Breast Cancer to predict response to Neoadjuvant Chemotherapy
Sponsor: Investigator initiated study
Enrolling: Male and Female Patients
IRB Number: AAAI0480
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: This study examines diffuse optical tomography (DOT) as a way to monitor the progress of the breast cancer therapy. Specifically, it looks at DOTs ability to detect non-responders early in treatment and then adjust the therapy to improve response and overall survival. DOT is favorable to more conventional forms of cancer monitoring, such as physical exams, mammograms, ultrasounds, and MRIs, because it can detect early changes to blood vessels that occur during tumor development. DOT is also less expensive and is less toxic as it does not use radiation.
This study is closed
Dawn Hershman, MD
Do You Qualify?
Are you a female over age 18 or older? Yes No
Do you have breast cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator